Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
4 hedge funds and large institutions have $7.5M invested in Plus Therapeutics in 2014 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
20% less funds holding
Funds holding: 5 → 4 (-1)
33% less capital invested
Capital invested by funds: $11.1M → $7.5M (-$3.62M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Goldman Capital Management
New York
|
-$1.36M |
| 2 |
Renaissance Technologies
New York
|
-$321K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$45K |
| 4 |
GS
Gagnon Securities
New York
|
-$38K |
| 5 |
AC
Amici Capital
New York
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Renaissance Technologies
New York
| – | -$321K | – | – |
|
77
SG Americas Securities
New York
| – | -$9K | – | – |
|
|
TRCT
78
Tower Research Capital (TRC)
New York
| – | -$25K | – | – |
|
|
79
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$45K | – | – |
|
PSTV Hedge Fund Activity: Q4 2014 in Review
4 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2014, worth a combined $7.5M — down 33% from $11.1M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PSTV and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Goldman Capital Management, exiting entirely with an estimated $1.36M sold.
- 4 institutional investors held Plus Therapeutics (PSTV) as of Q4 2014, down from 5 in Q3 2014.
- Funds reported $7.5M of Plus Therapeutics stock for Q4 2014, down 33% quarter-over-quarter.
- 0 funds opened new Plus Therapeutics positions in Q4 2014 and 1 closed out, a net change of -1 holder.
- The largest Plus Therapeutics seller in Q4 2014 was Goldman Capital Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q4 2014.